Piper Jaffray upgraded shares of Isis Pharmaceuticals (NASDAQ:ISIS) from an underweight rating to a neutral rating in a research note released on Tuesday morning, TheFlyOnTheWall.com reports. They currently have $38.00 target price on the stock, up from their previous target price of $25.00.
Isis Pharmaceuticals (NASDAQ:ISIS) traded up 3.17% on Tuesday, hitting $39.35. The stock had a trading volume of 962,451 shares. Isis Pharmaceuticals has a 52-week low of $8.69 and a 52-week high of $39.83. The stock has a 50-day moving average of $33.37 and a 200-day moving average of $29.19. The company’s market cap is $4.568 billion.
Isis Pharmaceuticals (NASDAQ:ISIS) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.21) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.27) by $0.06. The company had revenue of $23.60 million for the quarter, compared to the consensus estimate of $19.82 million. During the same quarter last year, the company posted ($0.37) earnings per share. Isis Pharmaceuticals’s revenue was up 103.4% compared to the same quarter last year. Analysts expect that Isis Pharmaceuticals will post $-0.53 EPS for the current fiscal year.
Other equities research analysts have also recently issued reports about the stock. Analysts at Zacks reiterated a neutral rating on shares of Isis Pharmaceuticals in a research note to investors on Thursday, November 7th. They now have a $33.00 price target on the stock. Separately, analysts at JPMorgan Chase & Co. initiated coverage on shares of Isis Pharmaceuticals in a research note to investors on Friday, October 4th. They set a neutral rating and a $37.00 price target on the stock. They noted that the move was a valuation call. Finally, analysts at Stifel Nicolaus raised their price target on shares of Isis Pharmaceuticals from $38.00 to $45.00 in a research note to investors on Tuesday, September 24th. They now have a buy rating on the stock. One analyst has rated the stock with a sell rating, six have issued a hold rating and four have given a buy rating to the company. Isis Pharmaceuticals currently has an average rating of Hold and a consensus target price of $36.18.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.